In a nutshell This trial aimed to evaluate the use of a second treatment targeting HER-2 in a group of patients that had HER-2, HR positive metastatic breast cancer. This study found that patients treated with dual HER-2 medications with hormone therapy had a superior progression free survival as compared to those using one medication...
Read More
In a nutshell This study investigated the effectiveness and safety of short 15-minute panitumumab (Vectibix) injections. Researchers suggested that these injections were well tolerated with manageable side effects. Some background Panitumumab is a therapy that targets the EFGR receptor on cancer cells. This blocks cell growth which results in cell...
Read More
In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...
Read More
In a nutshell This paper reviewed the risk of heart disease in patients receiving treatment for multiple myeloma. Reducing the risk of heart disease is important in patients with multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of blood. Treatment for multiple myeloma involves a group of drugs called proteasome...
Read More
In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients. Some background Chronic lymphocytic leukemia...
Read More
In a nutshell This study compared the outcomes of different salvage treatments in patients with aggressive B-cell non-Hodgkin lymphoma with PET-positive disease (remaining cancer cells) after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. This study concluded that B-cell NHL patients with PET-positive...
Read More
In a nutshell This study investigated the impact of white blood cell counts on the outcomes of newly diagnosed Hodgkin’s lymphoma (HL) patients receiving treatment mediated by PET2 (PET scanning after 2 cycles of chemotherapy). This study concluded that ratios of different types of white blood cells combined with PET2 can be a meaningful...
Read MoreIn a nutshell This study investigated the outcomes of classical Hodgkin’s lymphoma (cHL) patients who did or did not receive brentuximab vedotin (Adcetris) before allogeneic stem cell transplantation. This study concluded that pre-transplant brentuximab vedotin treatment does not lead to better post-transplant outcomes. Some background...
Read MoreIn a nutshell This paper compared the effect of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Ozurdex) to lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. The addition of carfilzomib was associated with a longer survival. Some background Multiple myeloma is a cancer of the...
Read MoreIn a nutshell This study determined if progression-free survival (time from treatment before disease progression) could be improved in patients with relapsed or refractory Hodgkin’s lymphoma (HL) who received two cycles (tandem) of autologous hematopoietic stem cell transplantation (AHSCT). This study concluded that tandem AHSCT appears effective...
Read More
In a nutshell This study determined long-term risk of death from all causes using data from 1,541 early-stage (stage 1-2) Hodgkin’s lymphoma (HL) patients who received radiotherapy (RT) alone or RT with chemotherapy. This study concluded that this risk was significantly lower for patients treated in the most recent era of radiation therapy thanks...
Read More
In a nutshell This phase 1 and 2 trial aims to determine the effectiveness and optimal dose of Axitinib and Bosutinib in patients with chronic myeloid leukemia. The outcome to be measured is the response to treatment based on genetic analysis and blood cell count, and the side effects. The study is located in Houston, Texas, United States. The...
Read More
